These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 35615902)

  • 1. Uptake of hepatitis B antiviral treatment: A panel data analysis of 31 provinces in China (2013-2020).
    Cheng H; Liu S; Luo S; Chan P; Chen Z; Le LV; Sun J
    Liver Int; 2022 Aug; 42(8):1762-1769. PubMed ID: 35615902
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Uptake of hepatitis C direct-acting antiviral treatment in China: a retrospective study from 2017 to 2021.
    Du X; Mi J; Cheng H; Song Y; Li Y; Sun J; Chan P; Chen Z; Luo S
    Infect Dis Poverty; 2023 Mar; 12(1):28. PubMed ID: 36978198
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Investment Case for a Comprehensive Package of Interventions Against Hepatitis B in China: Applied Modeling to Help National Strategy Planning.
    Nayagam S; Chan P; Zhao K; Sicuri E; Wang X; Jia J; Wei L; Walsh N; Rodewald LE; Zhang G; Ailing W; Zhang L; Chang JH; Hou W; Qiu Y; Sui B; Xiao Y; Zhuang H; Thursz MR; Scano F; Low-Beer D; Schwartländer B; Wang Y; Hallett TB
    Clin Infect Dis; 2021 Mar; 72(5):743-752. PubMed ID: 32255486
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Cost-effectiveness of community-based treatment of chronic hepatitis B in China].
    Zhang SX; Yang PC; Cai YL; Lin Y; Zou YH
    Zhonghua Liu Xing Bing Xue Za Zhi; 2017 Jul; 38(7):860-867. PubMed ID: 28738456
    [No Abstract]   [Full Text] [Related]  

  • 5. The impact of hepatitis B vaccine in China and in the China GAVI Project.
    Hadler SC; Fuqiang C; Averhoff F; Taylor T; Fuzhen W; Li L; Xiaofeng L; Weizhong Y
    Vaccine; 2013 Dec; 31 Suppl 9():J66-72. PubMed ID: 24331023
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [A typical investigation on the status of diagnosis and reporting of hepatitis B inpatients in non-surveillance hospitals in three provinces in China, 2015].
    Zheng H; Wang FZ; Zhang GM; Yuan QL; Miao N; Sun XJ
    Zhonghua Yu Fang Yi Xue Za Zhi; 2018 Oct; 52(10):1034-1038. PubMed ID: 30392323
    [No Abstract]   [Full Text] [Related]  

  • 7. Impact of National Volume-Based Procurement on the Procurement Volumes and Spending for Antiviral Medications of Hepatitis B Virus.
    Yuan J; Lu ZK; Xiong X; Lee TY; Huang H; Jiang B
    Front Pharmacol; 2022; 13():842944. PubMed ID: 35734415
    [No Abstract]   [Full Text] [Related]  

  • 8. Considerations of antiviral treatment to interrupt mother-to-child transmission of hepatitis B virus in China.
    Cui F; Woodring J; Chan P; Xu F
    Int J Epidemiol; 2018 Oct; 47(5):1529-1537. PubMed ID: 29757383
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Costs and health impact of delayed implementation of a national hepatitis B treatment program in China.
    Toy M; Hutton D; Jia J; So S
    J Glob Health; 2022 Jul; 12():04043. PubMed ID: 35796158
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [To improve the accessibility of hepatitis B treatment].
    Zhuang H
    Zhonghua Gan Zang Bing Za Zhi; 2016 Jun; 24(6):401-2. PubMed ID: 27465940
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The inception, achievements, and implications of the China GAVI Alliance Project on Hepatitis B Immunization.
    Kane MA; Hadler SC; Lee L; Shapiro CN; Cui F; Wang X; Kumar R
    Vaccine; 2013 Dec; 31 Suppl 9():J15-20. PubMed ID: 24331015
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The price tag of a potential cure for chronic hepatitis B infection: A cost threshold analysis for USA, China and Australia.
    Toy M; Hutton D; McCulloch K; Romero N; Revill PA; Penicaud MC; So S; Cowie BC
    Liver Int; 2022 Jan; 42(1):16-25. PubMed ID: 34328697
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Recognizing the impact of endemic hepatitis D virus on hepatitis B virus eradication.
    Goyal A; Murray JM
    Theor Popul Biol; 2016 Dec; 112():60-69. PubMed ID: 27594346
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Self-motivated medical care-seeking behaviors and disease progression in a community-based cohort of chronic hepatitis B virus-infected patients in China.
    Zheng H; Zhang G; Wang F; Yin Z; Miao N; Sun X; Liang X; Cui F
    BMC Public Health; 2019 Jul; 19(1):901. PubMed ID: 31286924
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Requirements for global elimination of hepatitis B: a modelling study.
    Nayagam S; Thursz M; Sicuri E; Conteh L; Wiktor S; Low-Beer D; Hallett TB
    Lancet Infect Dis; 2016 Dec; 16(12):1399-1408. PubMed ID: 27638356
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Countdown to 2030: eliminating hepatitis B disease, China.
    Liu J; Liang W; Jing W; Liu M
    Bull World Health Organ; 2019 Mar; 97(3):230-238. PubMed ID: 30992636
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Promoting hepatitis B elimination and laying emphasis on its economics evaluation].
    Zhang SX
    Zhonghua Liu Xing Bing Xue Za Zhi; 2017 Jul; 38(7):841-844. PubMed ID: 28738453
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Moving towards hepatitis B elimination in Gulf Health Council states: From commitment to action.
    Al Awaidy ST; Ezzikouri S
    J Infect Public Health; 2020 Feb; 13(2):221-227. PubMed ID: 31445879
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Socioeconomic inequality in Hepatitis B vaccination of rural adults in China.
    Zhu D; Guo N; Wang J; Nicholas S; Wang Z; Zhang G; Shi L; Wangen KR
    Hum Vaccin Immunother; 2018 Feb; 14(2):464-470. PubMed ID: 29072546
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Progress and challenges in achieving the WHO goal on 'Elimination of Hepatitis B by 2030' in China].
    Liu J; Liu M
    Zhonghua Liu Xing Bing Xue Za Zhi; 2019 Jun; 40(6):605-609. PubMed ID: 31238605
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.